De-novo and acquired resistance to immune checkpoint targeting
- PMID: 29208439
- DOI: 10.1016/S1470-2045(17)30607-1
De-novo and acquired resistance to immune checkpoint targeting
Abstract
Use of immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated protein-4 axes has yielded impressive results in some clinical trials. However, only a subset of patients initially respond to these inhibitors, and increasing clinical evidence indicates that a substantial proportion of initial responders ultimately relapse with lethal, drug-resistant disease months or years later. Studies that have used massively parallel sequencing have shed light on the rich functional landscape of mutations that endow tumour cells with the ability to evade T-cell-mediated immunosurveillance. Cancer genomes bear signatures of clonal evolution and selection, particularly implicating acquired defects in interferon receptor signalling and antigen presentation. In this Review, we discuss the biological processes that operate in the formation of so-called immunoresistant niches, and describe the latest progress in the development of combination strategies to reinstate immunosurveillance in immune-refractory tumours.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17. Bull Cancer. 2019. PMID: 30342749 Review.
-
Biomarkers of response to immune checkpoint blockade in cancer treatment.Crit Rev Oncol Hematol. 2018 Oct;130:108-120. doi: 10.1016/j.critrevonc.2018.07.010. Epub 2018 Aug 3. Crit Rev Oncol Hematol. 2018. PMID: 30196907 Review.
-
New checkpoint inhibitors ride the immunotherapy tsunami.Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066. Nat Rev Drug Discov. 2013. PMID: 23812256 No abstract available.
-
Progress of immune checkpoint therapy in the clinic (Review).Oncol Rep. 2019 Jan;41(1):3-14. doi: 10.3892/or.2018.6819. Epub 2018 Oct 24. Oncol Rep. 2019. PMID: 30365127 Review.
-
PD-1/PD-L1 and immunotherapy for pancreatic cancer.Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18. Cancer Lett. 2017. PMID: 28826722 Review.
Cited by
-
Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment.Quant Imaging Med Surg. 2021 Jun;11(6):2837-2860. doi: 10.21037/qims-20-173. Quant Imaging Med Surg. 2021. PMID: 34079746 Free PMC article. Review.
-
ROCKETS - a novel one-for-all toolbox for light sheet microscopy in drug discovery.Front Immunol. 2023 Feb 7;14:1034032. doi: 10.3389/fimmu.2023.1034032. eCollection 2023. Front Immunol. 2023. PMID: 36845124 Free PMC article.
-
Advances in Immunotherapies for Gliomas.Curr Neurol Neurosci Rep. 2022 Jan;22(1):1-10. doi: 10.1007/s11910-022-01176-9. Epub 2022 Feb 2. Curr Neurol Neurosci Rep. 2022. PMID: 35107784 Free PMC article. Review.
-
Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins.Front Oncol. 2022 Mar 23;12:808475. doi: 10.3389/fonc.2022.808475. eCollection 2022. Front Oncol. 2022. PMID: 35402235 Free PMC article. Review.
-
The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy.Eye (Lond). 2019 Feb;33(2):176-182. doi: 10.1038/s41433-018-0279-9. Epub 2018 Dec 7. Eye (Lond). 2019. PMID: 30531993 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials